FBXO9

Summary

FBXO9 (F-box protein 9, HGNC:13588) is a protein-coding gene on chromosome 6p12.1, encoding F-box only protein 9 (Q9UK97). Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferat….

This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. Alternative splicing of this gene generates at least 3 transcript variants diverging at the 5’ terminus.

Source: NCBI Gene 26268 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 60 total
• MANE Select transcript: NM_033480

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13588
Approved symbol	FBXO9
Name	F-box protein 9
Location	6p12.1
Locus type	gene with protein product
Status	Approved
Aliases	FBX9, NY-REN-57
Ensembl gene	ENSG00000112146
Ensembl biotype	protein_coding
OMIM	609091
Entrez	26268

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 8 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000244426, ENST00000323557, ENST00000370939, ENST00000459845, ENST00000461222, ENST00000468481, ENST00000473318, ENST00000473337, ENST00000474457, ENST00000480463, ENST00000484436, ENST00000484812, ENST00000498744

RefSeq mRNA: 3 — MANE Select: NM_033480 NM_012347, NM_033480, NM_033481

CCDS: CCDS55022, CCDS55023, CCDS55024

Canonical transcript exons

ENST00000323557 — 13 exons

Exon	Start	End
ENSE00000756521	53092734	53092824
ENSE00000756524	53093466	53093561
ENSE00001436570	53065404	53065792
ENSE00001534301	53097722	53100873
ENSE00003463492	53078799	53078898
ENSE00003519430	53076486	53076543
ENSE00003549381	53073481	53073639
ENSE00003569493	53071057	53071143
ENSE00003680521	53092429	53092547
ENSE00003683436	53082504	53082618
ENSE00003706677	53093885	53093978
ENSE00003709797	53095513	53095664
ENSE00003786194	53080968	53081098

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.5270 / max 822.0264, expressed in 1824 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
68248	42.2749	1823
68249	2.3910	1341
68250	0.6744	357
68247	0.1867	69

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	99.29	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.18	gold quality
middle temporal gyrus	UBERON:0002771	99.12	gold quality
right adrenal gland	UBERON:0001233	98.92	gold quality
right adrenal gland cortex	UBERON:0035827	98.87	gold quality
esophagus squamous epithelium	UBERON:0006920	98.86	gold quality
secondary oocyte	CL:0000655	98.85	gold quality
left adrenal gland	UBERON:0001234	98.83	gold quality
trabecular bone tissue	UBERON:0002483	98.81	gold quality
left adrenal gland cortex	UBERON:0035825	98.81	gold quality
adrenal cortex	UBERON:0001235	98.76	gold quality
tibia	UBERON:0000979	98.66	gold quality
parotid gland	UBERON:0001831	98.66	gold quality
Brodmann (1909) area 10	UBERON:0013541	98.63	gold quality
germinal epithelium of ovary	UBERON:0001304	98.45	gold quality
adrenal gland	UBERON:0002369	98.42	gold quality
pons	UBERON:0000988	98.35	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.28	gold quality
squamous epithelium	UBERON:0006914	98.17	gold quality
choroid plexus epithelium	UBERON:0003911	98.06	gold quality
visceral pleura	UBERON:0002401	97.97	gold quality
renal glomerulus	UBERON:0000074	97.96	gold quality
parietal pleura	UBERON:0002400	97.90	gold quality
pleura	UBERON:0000977	97.88	gold quality
gingival epithelium	UBERON:0001949	97.87	gold quality
body of pancreas	UBERON:0001150	97.86	gold quality
metanephric glomerulus	UBERON:0004736	97.84	gold quality
nephron tubule	UBERON:0001231	97.83	gold quality
palpebral conjunctiva	UBERON:0001812	97.78	gold quality
occipital lobe	UBERON:0002021	97.78	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-10042	yes	23.62
E-MTAB-9221	yes	13.02
E-MTAB-6678	no	4.06
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

122 targeting FBXO9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548P	99.98	72.25	3784
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-4760-3P	99.93	70.50	2385

Literature-anchored findings (GeneRIF, showing 2)

• ICK and FBX9 are divergently transcribed from a bidirectional promoter that is GC-rich and contains a CpG island. (PMID:20459822)
• F-box only protein 9 and its role in cancer. (PMID:35025031)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fbxo9	ENSDARG00000011055
mus_musculus	Fbxo9	ENSMUSG00000001366
rattus_norvegicus	Fbxo9	ENSRNOG00000008214
drosophila_melanogaster	CG5961	FBGN0038056

Protein

Protein identifiers

F-box only protein 9 — Q9UK97 (reviewed: Q9UK97)

Alternative names: Cross-immune reaction antigen 1, Renal carcinoma antigen NY-REN-57

All UniProt accessions (6): Q9UK97, C9IY65, C9J4V1, C9JDZ9, H7C4H6, V9GZ74

UniProt curated annotations — full annotation on UniProt →

Function. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability. Ubiquitinates mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is the activated due to the relief of feedback inhibition by mTORC1. Plays a role in maintaining epithelial cell survival by regulating the turn-over of chromatin modulator PRMT4 through ubiquitination and degradation by the proteasomal pathway. Regulates also PPARgamma stability by facilitating PPARgamma/PPARG ubiquitination and thereby plays a role in adipocyte differentiation.

Subunit / interactions. Part of the SCF (SKP1-CUL1-F-box) E3 ubiquitin-protein ligase complex SCF(FBXO9) composed of CUL1, SKP1, RBX1 and FBXO9. Interacts with TTI1 and TELO2; when TTI1 and TELO2 are phosphorylated by CK2.

Subcellular location. Cytoplasm.

Pathway. Protein modification; protein ubiquitination.

Miscellaneous. Overexpressed in multiple myeloma leading to constitutive activation of the PI(3)K/mTORC2/Akt pathway to promote survival.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UK97-1	1	yes
Q9UK97-2	2
Q9UK97-3	3

RefSeq proteins (3): NP_036479, NP_258441, NP_258442 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001810	F-box_dom	Domain
IPR036047	F-box-like_dom_sf	Homologous_superfamily
IPR036181	MIT_dom_sf	Homologous_superfamily
IPR045464	Hrt3/FBXO9_C	Domain

Pfam: PF12937, PF19270

UniProt features (8 total): splice variant 2, chain 1, repeat 1, domain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UK97-F1	78.07	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 136

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 196 (showing top): E2F_Q4_01, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, TGCGCANK_UNKNOWN, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, MORF_HDAC1, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GGCNKCCATNK_UNKNOWN, BILD_HRAS_ONCOGENIC_SIGNATURE, chr6p12, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, YY1_02, BLALOCK_ALZHEIMERS_DISEASE_UP, MORF_CTBP1

GO Biological Process (9): protein ubiquitination (GO:0016567), SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146), regulation of TOR signaling (GO:0032006), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), innate immune response (GO:0045087), fat cell differentiation (GO:0045444), protein K48-linked ubiquitination (GO:0070936), apoptotic process (GO:0006915), positive regulation of epithelial cell apoptotic process (GO:1904037)

GO Molecular Function (3): ubiquitin-protein transferase activity (GO:0004842), ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (4): ubiquitin ligase complex (GO:0000151), cytoplasm (GO:0005737), cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein modification by small protein conjugation	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
TOR signaling	1
regulation of intracellular signal transduction	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
immune response	1
defense response to symbiont	1
cell differentiation	1
protein polyubiquitination	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
positive regulation of apoptotic process	1
epithelial cell apoptotic process	1
regulation of epithelial cell apoptotic process	1
ubiquitin-like protein transferase activity	1
enzyme-substrate adaptor activity	1
binding	1
intracellular protein-containing complex	1
transferase complex	1
intracellular anatomical structure	1
cytoplasm	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

1058 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FBXO9	CUL1	Q13616	828
FBXO9	SKP1	P34991	816
FBXO9	FBXO4	Q9UKT5	639
FBXO9	TTI1	O43156	579
FBXO9	FBXO11	Q86XK2	572
FBXO9	FBXL3	Q9UKT7	517
FBXO9	FBXO45	P0C2W1	494
FBXO9	RSPRY1	Q96DX4	490
FBXO9	UBE2G1	P62253	479
FBXO9	FBXW8	Q8N3Y1	477
FBXO9	CCDC106	Q9BWC9	475
FBXO9	FBH1	Q8NFZ0	469
FBXO9	FBXO28	Q9NVF7	468
FBXO9	TELO2	Q9Y4R8	453
FBXO9	FBXO10	Q9UK96	449

IntAct

39 interactions, top by confidence:

A	B	Type	Score
FBXO9	SKP1	psi-mi:“MI:0915”(physical association)	0.740
SKP1	MYCBP2	psi-mi:“MI:0914”(association)	0.640
FBXO9	TELO2	psi-mi:“MI:0915”(physical association)	0.610
FBXO9	TTI1	psi-mi:“MI:0914”(association)	0.610
FBXO9	TTI1	psi-mi:“MI:0915”(physical association)	0.610
CUL1	FBXO21	psi-mi:“MI:0914”(association)	0.600
GFOD1	PER1	psi-mi:“MI:0914”(association)	0.530
RICTOR	TTI1	psi-mi:“MI:0914”(association)	0.460
RPTOR	TTI1	psi-mi:“MI:0914”(association)	0.460
SKP1	FBXO9	psi-mi:“MI:0915”(physical association)	0.400
FBXO9	EEF2	psi-mi:“MI:0915”(physical association)	0.400
FBXO9	HSP90AB1	psi-mi:“MI:0915”(physical association)	0.400
SPG11	FBXO9	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
FBXO9	MTOR	psi-mi:“MI:0914”(association)	0.350
CUL1	LGALS8	psi-mi:“MI:0914”(association)	0.350
COPS5	FBLL1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
S100P	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
SKP1	BHLHE40	psi-mi:“MI:0914”(association)	0.350
RBX1	OBSL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (36): FBXO9 (Affinity Capture-MS), SKP1 (Affinity Capture-Western), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), EEF2 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-Western), SKP1 (Two-hybrid), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), FBXO9 (Affinity Capture-MS), EEF2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8GLK3, A0A974CYQ5, A2AHJ4, A5WW08, D2HNY3, D2HWM5, E7F6T8, F1ND48, O75717, O88907, O95071, P59328, Q28DL4, Q3TLR7, Q4V837, Q58WW2, Q5E9J6, Q5FWP4, Q5NVC7, Q5R9B8, Q5RF77, Q5RGA4, Q5RHI5, Q5ZLG9, Q62671, Q66JG1, Q6AXK4, Q6DDH2, Q6NVE8, Q6P1W0, Q6P256, Q6PCD5, Q6PJI9, Q6RI45, Q80TP3, Q80U93, Q810L3, Q8C0M0, Q8CBW4, Q8CIK8

Diamond homologs: F6Y9J3, O74531, Q3ZBT2, Q5U2X1, Q6P3K3, Q8BK06, Q9UK97, Q9XI00

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
FBXO9	“down-regulates quantity by destabilization”	TELO2	binding
FBXO9	“down-regulates quantity by destabilization”	TTI1	binding
FBXO9	“down-regulates activity”	“Cullin 1-RBX1-Skp1”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 37 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neddylation	6	10.9×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2494 predictions. Top by Δscore:

Variant	Effect	Δscore
6:53061594:A:AC	donor_gain	1.0000
6:53061595:C:CC	donor_gain	1.0000
6:53061595:CTGG:C	donor_gain	1.0000
6:53065670:C:G	donor_gain	1.0000
6:53071055:A:AG	acceptor_gain	1.0000
6:53071056:G:GT	acceptor_gain	1.0000
6:53071056:GGC:G	acceptor_gain	1.0000
6:53071056:GGCA:G	acceptor_gain	1.0000
6:53073476:CATA:C	acceptor_loss	1.0000
6:53073478:TA:T	acceptor_loss	1.0000
6:53073479:A:AG	acceptor_gain	1.0000
6:53073479:A:AT	acceptor_loss	1.0000
6:53073480:G:GA	acceptor_loss	1.0000
6:53073480:G:GG	acceptor_gain	1.0000
6:53073480:GGC:G	acceptor_gain	1.0000
6:53073480:GGCAC:G	acceptor_gain	1.0000
6:53073626:C:T	donor_gain	1.0000
6:53073634:GAAAA:G	donor_gain	1.0000
6:53073640:T:TG	donor_gain	1.0000
6:53073644:G:GG	donor_gain	1.0000
6:53076481:TATAG:T	acceptor_loss	1.0000
6:53076483:TAGGC:T	acceptor_loss	1.0000
6:53078797:A:AG	acceptor_gain	1.0000
6:53078798:G:GG	acceptor_gain	1.0000
6:53078895:GCTA:G	donor_gain	1.0000
6:53078899:G:GG	donor_gain	1.0000
6:53080966:A:AG	acceptor_gain	1.0000
6:53080967:G:GA	acceptor_gain	1.0000
6:53080967:GC:G	acceptor_gain	1.0000
6:53080967:GCATT:G	acceptor_gain	1.0000

AlphaMissense

2896 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:53076543:G:C	A113P	1.000
6:53078814:G:C	R118P	1.000
6:53078819:G:C	A120P	1.000
6:53078820:C:A	A120D	1.000
6:53095633:T:A	W402R	1.000
6:53095633:T:C	W402R	1.000
6:53076498:T:C	F98L	0.999
6:53076499:T:C	F98S	0.999
6:53076500:C:A	F98L	0.999
6:53076500:C:G	F98L	0.999
6:53076507:G:C	A101P	0.999
6:53076508:C:A	A101E	0.999
6:53078799:C:A	A113D	0.999
6:53078810:T:G	Y117D	0.999
6:53078829:T:C	L123P	0.999
6:53078841:T:A	I127K	0.999
6:53092547:G:C	G268R	0.999
6:53092734:G:A	G268D	0.999
6:53092763:C:A	R278S	0.999
6:53092764:G:C	R278P	0.999
6:53092769:G:A	G280R	0.999
6:53092769:G:C	G280R	0.999
6:53092824:G:T	R298M	0.999
6:53093534:T:A	V321D	0.999
6:53093904:G:C	G337R	0.999
6:53093905:G:A	G337D	0.999
6:53095589:T:C	L387P	0.999
6:53095628:T:A	L400H	0.999
6:53095628:T:C	L400P	0.999
6:53095645:T:C	S406P	0.999

dbSNP variants (sampled 300 via entrez): RS1000044763 (6:53056742 A>G), RS1000073603 (6:53063899 C>T), RS1000095883 (6:53080432 C>A,T), RS1000109191 (6:53087362 A>G), RS1000426908 (6:53080725 C>T), RS1000501944 (6:53083159 T>C), RS1000532624 (6:53083662 T>C), RS1000540836 (6:53075657 T>C), RS1000774213 (6:53090512 CAAAG>C), RS1000774305 (6:53095886 T>C), RS1000833318 (6:53068523 TAA>T), RS1000867745 (6:53089942 A>C,G), RS1000875990 (6:53090256 A>G), RS1001201150 (6:53069081 C>A), RS1001209789 (6:53057282 A>G)

Disease associations

OMIM: gene MIM:609091 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003181_5	Staphylococcus aureus nasal carriage (intermittent)	9.000000e-06
GCST90000047_120	Age at first sexual intercourse	5.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007758	intermittent Staphylococcus aureus carrier status
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, decreases methylation, increases expression	6
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
Formaldehyde	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, affects expression	2
Silicon Dioxide	decreases expression	2
Tretinoin	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases expression, increases methylation	1
lead acetate	decreases expression	1
trichostatin A	decreases expression, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	increases expression	1
nickel sulfate	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, affects expression	1
abrine	decreases expression	1
dorsomorphin	affects expression, affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Panobinostat	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Cisplatin	decreases reaction, increases expression	1
Dinitrochlorobenzene	decreases expression	1
Ethyl Methanesulfonate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.